Olaparib: tested on its own
100 studies: no other medicine in its arm. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian CancerRecruitingNCT07460180Phase 1/2Report a problem
- Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian CancerRecruitingNCT07371104Phase 1Report a problem
- A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian CancerRecruitingNCT07069335Phase 1Report a problem
- Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial CancerRecruitingNCT06712472Phase 3Report a problem
- Olaparib in PALB2 Advanced Pancreatic CancerRecruitingNCT06078787Phase 2Report a problem
- Improving Peptide Receptor Radionuclide Therapy With PARP InhibitorsRecruitingNCT05870423Phase 1Report a problem
- Olaparib Maintenance Therapy in Metastatic Breast CancerRecruitingNCT05629429Phase 2Report a problem
- Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNot yet recruitingNCT05522491Phase 2Report a problem
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3Report a problem
- MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal CancerRecruitingNCT05233982Phase 2Report a problem
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingNCT04858334Phase 2Report a problem
- Olaparib in Patients With HRD Malignant MesotheliomaRecruitingNCT04515836Phase 2Report a problem
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsRecruitingNCT03786796Phase 2Report a problem
- Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingNCT05457257Phase 4Results postedReport a problem
- Olaparib in Subjects With Advanced Pancreatic Acinar Cell CarcinomaTerminatedNCT05286827Phase 2Results postedReport a problem
- Olaparib for the Treatment of Castration Resistant Prostate AdenocarcinomaTerminatedNCT04951492Phase 2Results postedReport a problem
- Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian CancerTerminatedNCT04377087Phase 2Results postedReport a problem
- Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast CancerCompletedNCT04330040Phase 4Results postedReport a problem
- Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene MutationsActive, not recruitingNCT04042831Phase 2Results postedReport a problem
- Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationActive, not recruitingNCT03953898Phase 2Results postedReport a problem
- Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)Active, not recruitingNCT03742895Phase 2Results postedReport a problem
- Olaparib Before Surgery in Treating Participants With Localized Prostate CancerTerminatedNCT03570476Phase 2Results postedReport a problem
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompletedNCT03534453Phase 3Results postedReport a problem
- Olaparib in People With Malignant MesotheliomaCompletedNCT03531840Phase 2Results postedReport a problem
- Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene AlterationsCompletedNCT03448718Phase 2Results postedReport a problem
- Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer PatientsCompletedNCT03402841Phase 3Results postedReport a problem
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone MetastasisActive, not recruitingNCT03317392Phase 1/2Results postedReport a problem
- To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.CompletedNCT03286842Phase 3Results postedReport a problem
- Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results postedReport a problem
- Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT03212274Phase 2Results postedReport a problem
- Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast CancerCompletedNCT03205761Phase 2Results postedReport a problem
- A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.CompletedNCT03106987Phase 3Results postedReport a problem
- Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker AnalysisActive, not recruitingNCT03047135Phase 2Results postedReport a problem
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)CompletedNCT02987543Phase 3Results postedReport a problem
- Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusCompletedNCT02983799Phase 2Results postedReport a problem
- A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue SarcomaCompletedNCT02787642Phase 1Results postedReport a problem
- Olaparib in Treating Patients With Stage IV Pancreatic CancerCompletedNCT02677038Phase 2Results postedReport a problem
- To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerCompletedNCT02476968Phase 4Results postedReport a problem
- Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum TreatmentsCompletedNCT02282020Phase 3Results postedReport a problem
- Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based ChemotherapyCompletedNCT02184195Phase 3Results postedReport a problem
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerActive, not recruitingNCT02032823Phase 3Results postedReport a problem
- Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.CompletedNCT02000622Phase 3Results postedReport a problem
- Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyActive, not recruitingNCT01874353Phase 3Results postedReport a problem
- Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.Active, not recruitingNCT01844986Phase 3Results postedReport a problem
- Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid MalignanciesCompletedNCT01813474Phase 1Results postedReport a problem
- Olaparib in Adults With Recurrent/Metastatic Ewing's SarcomaCompletedNCT01583543Phase 2Results postedReport a problem
- Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation PatsCompletedNCT01078662Phase 2Results postedReport a problem
- Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) StatusCompletedNCT00912743Phase 2Results postedReport a problem
- Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerCompletedNCT00753545Phase 2Results postedReport a problem
- Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerCompletedNCT00679783Phase 2Results postedReport a problem
- Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerCompletedNCT00628251Phase 2Results postedReport a problem
- Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian CancerCompletedNCT00494442Phase 2Results postedReport a problem
- Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerCompletedNCT00494234Phase 2Results postedReport a problem
- Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination DeficiencyWithdrawnNCT06120972Phase 2Report a problem
- Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2WithdrawnNCT05482074Phase 2Report a problem
- Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.CompletedNCT05340413Phase 2Report a problem
- Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer PatientsCompletedNCT05320757Early Phase 1Report a problem
- The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene MutationStatus unknownNCT05262608Phase 2Report a problem
- D9319C00001- 1L OC Mono Global RCTActive, not recruitingNCT04884360Phase 3Report a problem
- Functional Analysis of BRCAnessTerminatedNCT04780945Phase 2Report a problem
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3Report a problem
- Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid TumoursCompletedNCT04236414Phase 1Report a problem
- Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2Report a problem
- PARP Inhibition During Pre-surgical Window in Breast/Ovary CancerCompletedNCT04041128Early Phase 1Report a problem
- Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination GenesActive, not recruitingNCT03967938Phase 2Report a problem
- Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall RecurrencesTerminatedNCT03955640Phase 1Report a problem
- A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric CancerStatus unknownNCT03829345Phase 2Report a problem
- Olaparib for PAH: a Multicenter Clinical TrialTerminatedNCT03782818Phase 1/2Report a problem
- UTOLA: UTerin OLAparibCompletedNCT03745950Phase 2Report a problem
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerActive, not recruitingNCT03598257Phase 2Report a problem
- Olaparib in Recurrent IDH-mutant GliomaCompletedNCT03561870Phase 2Report a problem
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian CarcinomaCompletedNCT03470805Phase 2Report a problem
- Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)CompletedNCT03434158Phase 2Report a problem
- Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingNCT03375307Phase 2Report a problem
- A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single AgentTerminatedNCT03367689Phase 2Report a problem
- Olaparib In Metastatic Breast CancerActive, not recruitingNCT03344965Phase 2Report a problem
- Olaparib for PAH: a Pilot StudyTerminatedNCT03251872Early Phase 1Report a problem
- Resistant Ovarian Cancer, Olaparib and Liposomal DoxorubicinCompletedNCT03161132Phase 2Report a problem
- Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)CompletedNCT03109080Phase 1Report a problem
- Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A MutationsCompletedNCT03009682Phase 2Report a problem
- Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian CancerStatus unknownNCT02822157Phase 2Report a problem
- Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCCWithdrawnNCT02686008Phase 1Report a problem
- Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer PatientsStatus unknownNCT02681562Phase 2Report a problem
- Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung CancerTerminatedNCT02679963Phase 2Report a problem
- Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell TumorCompletedNCT02533765Phase 2Report a problem
- Efficacy and Safety of PARPi to Treat Pancreatic CancerCompletedNCT02511223Phase 2Report a problem
- Platine, Avastin and OLAparib in 1st LineCompletedNCT02477644Phase 3Report a problem
- Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3Report a problem
- Olaparib and Radiotherapy in Head and Neck CancerActive, not recruitingNCT02229656Phase 1Report a problem
- Olaparib and Radiotherapy in Inoperable Breast CancerCompletedNCT02227082Phase 1Report a problem
- To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid TumoursCompletedNCT01921140Phase 1Report a problem
- D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid TumoursCompletedNCT01851265Phase 1Report a problem
- Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)Status unknownNCT01788332Phase 2Report a problem
- TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate CancerStatus unknownNCT01682772Phase 2Report a problem
- Olaparib for Patients With Recurrent BRCA Deficient Ovarian CancerWithdrawnNCT01661868Phase 2Report a problem
- Radiotherapy & Olaparib in COmbination for Carcinoma of the OesophagusStatus unknownNCT01460888Phase 1Report a problem
- Phase I Comparative Bioavailability StudyActive, not recruitingNCT00777582Phase 1Report a problem
- Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic TumoursCompletedNCT00633269Phase 1Report a problem
- Open Label, Dose Escalation Phase I Study of AZD2281CompletedNCT00572364Phase 1Report a problem
- A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)CompletedNCT00516373Phase 1Report a problem